Up-regulation of P21 inhibits TRAIL-mediated extrinsic apoptosis, contributing resistance to SAHA in acute myeloid leukemia cells

Cellular Physiology and Biochemistry

Volumn 34, Issue 2, 2014, Pages 506-518

  Wu, Xing ^a,b,c,e   Yang, Na ^a,b,e   Zhou, Wei Hua ^d   Xu, Jie ^d   Chen, Jia Jie ^a,e   Zheng, Fei Meng ^b   Long, Zi Jie ^a,e   Yue, Cai Feng ^b   Ai, Ke Xin ^a,e   Liu, Ling Ling ^a,e   Wan, Xian Yao ^e   Liu, Quentin ^a,b,e  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^d NANCHANG UNIVERSITY   (China)

^e DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Histone deacetylase inhibitors; P21; SAHA; TRAIL

Indexed keywords

BIOLOGICAL MARKER; LIPOCORTIN 5; PROTEIN P21; RAPAMYCIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VORINOSTAT; CASPASE 8; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE DEACETYLASE INHIBITOR; TNFSF10 PROTEIN, HUMAN; ANTIBIOTIC G 418; PROTEIN SERINE THREONINE KINASE INHIBITOR; SMALL INTERFERING RNA;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; GENE TARGETING; HL 60 CELL LINE; HUMAN; HUMAN CELL; LETHALITY; MTT ASSAY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPLEMENTATION; TREATMENT RESPONSE; U937 CELL LINE; UPREGULATION; WESTERN BLOTTING; DRUG RESISTANCE; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; CANCER COMBINATION CHEMOTHERAPY; CELL COUNT; CELL FUNCTION; CELL SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; G1 PHASE CELL CYCLE CHECKPOINT; GENE PRODUCT; INVESTIGATIVE PROCEDURES; SENSITIVITY ANALYSIS; VIRUS INFECTION;

APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CASPASE 8; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HISTONE DEACETYLASE INHIBITORS; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; RNA INTERFERENCE; SIROLIMUS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 84907334148     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000363018     Document Type: Article

References (33)

1. Kumar CC: Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer 2011;2:95-107.
2. Farag SS, Ruppert AS, Mrozek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR, Stamberg J, Baer MR, Block AW, Vardiman JW, Kolitz JE, Schiffer CA, Larson RA, Bloomfield CD: Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A cancer and leukemia group b study. J Clin Oncol 2005;23:482-493.
3. Klepin HD, Balducci L: Acute myelogenous leukemia in older adults. Oncologist 2009;14:222-232.
4. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [saha]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111:1060-1066.
5. Gojo I, Tan M, Fang HB, Sadowska M, Lapidus R, Baer MR, Carrier F, Beumer JH, Anyang BN, Srivastava RK, Espinoza-Delgado I, Ross DD: Translational phase i trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res 2013;19:1838-1851.
6. Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD: A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009;94:1375-1382.
7. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, de Lera AR, Gronemeyer H, Altucci L: Tumor-selective action of hdac inhibitors involves trail induction in acute myeloid leukemia cells. Nat Med 2005;11:77-84.
8. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T: Histone deacetylase inhibitors upregulate death receptor 5/trail-r2 and sensitize apoptosis induced by trail/apo2-l in human malignant tumor cells. Oncogene 2004;23:6261-6271.
9. Richon VM, Sandhoff TW, Rifkind RA, Marks PA: Histone deacetylase inhibitor selectively induces p21waf1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000;97:10014-10019.
10. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, Johnstone RW: Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005;102:3697-3702.
11. Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, Ehinger M, Fisher PB, Grant S: Induction of apoptosis in u937 human leukemia cells by suberoylanilide hydroxamic acid (saha) proceeds through pathways that are regulated by bcl-2/bcl-xl, c-jun, and p21cip1, but independent of p53. Oncogene 1999;18:7016-7025.
12. Burgess AJ, Pavey S, Warrener R, Hunter LJ, Piva TJ, Musgrove EA, Saunders N, Parsons PG, Gabrielli BG: Up-regulation of p21(waf1/cip1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 2001;60:828-837.
13. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O: A synthetic inhibitor of histone deacetylase, ms-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A 1999;96:4592-4597.
14. Chiang CT, Way TD, Lin JK: Sensitizing her2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(waf1/cip1) expression with rapamycin. Mol Cancer Ther 2007;6:2127-2138.
15. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S: Apoptosis inhibitory activity of cytoplasmic p21(cip1/waf1) in monocytic differentiation. EMBO J 1999;18:1223-1234.
16. Suzuki A, Tsutomi Y, Akahane K, Araki T, Miura M: Resistance to fas-mediated apoptosis: Activation of caspase 3 is regulated by cell cycle regulator p21waf1 and iap gene family ilp. Oncogene 1998;17:931-939.
17. Sohn D, Essmann F, Schulze-Osthoff K, Janicke RU: P21 blocks irradiation-induced apoptosis downstream of mitochondria by inhibition of cyclin-dependent kinase-mediated caspase-9 activation. Cancer Res 2006;66:11254-11262.
18. Aneja R, Ghaleb AM, Zhou J, Yang VW, Joshi HC: P53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res 2007;67:3862-3870.
19. Hassani S, Ghaffari SH, Zaker F, Mirzaee R, Mardani H, Bashash D, Zekri A, Yousefi M, Zaghal A, Alimoghaddam K, Ghavamzadeh A: Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of g2/m arrest. Ann Hematol 2013;92:1207-1220.
20. Suzuki H, Yabuta N, Okada N, Torigata K, Aylon Y, Oren M, Nojima H: Lats2 phosphorylates p21/cdkn1a after uv irradiation and regulates apoptosis. J Cell Sci 2013;126:4358-4368.
21. Gartel AL, Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-649.
22. Kwon SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee YW, Lee HW, Han JW: Apicidin, a histone deacetylase inhibitor, induces apoptosis and fas/fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 2002;277:2073-2080.
23. Adachi S, Ito H, Tamamori-Adachi M, Ono Y, Nozato T, Abe S, Ikeda M, Marumo F, Hiroe M: Cyclin a/cdk2 activation is involved in hypoxia-induced apoptosis in cardiomyocytes. Circ Res 2001;88:408-414.
24. Jin YH, Yoo KJ, Lee YH, Lee SK: Caspase 3-mediated cleavage of p21waf1/cip1 associated with the cyclin a-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in sk-hep-1 cells. J Biol Chem 2000;275:30256-30263.
25. Seol DW, Li J, Seol MH, Park SY, Talanian RV, Billiar TR: Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (trail): Caspase-8 is required for trail-induced apoptosis. Cancer Res 2001;61:1138-1143.
26. Uno K, Inukai T, Kayagaki N, Goi K, Sato H, Nemoto A, Takahashi K, Kagami K, Yamaguchi N, Yagita H, Okumura K, Koyama-Okazaki T, Suzuki T, Sugita K, Nakazawa S: Tnf-related apoptosis-inducing ligand (trail) frequently induces apoptosis in philadelphia chromosome-positive leukemia cells. Blood 2003;101:3658-3667.
27. Steinwede K, Henken S, Bohling J, Maus R, Ueberberg B, Brumshagen C, Brincks EL, Griffith TS, Welte T, Maus UA: Tnf-related apoptosis-inducing ligand (trail) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. J Exp Med 2012;209:1937-1952.
28. Galligan L, Longley DB, McEwan M, Wilson TR, McLaughlin K, Johnston PG: Chemotherapy and trail-mediated colon cancer cell death: The roles of p53, trail receptors, and c-flip. Mol Cancer Ther 2005;4:2026-2036.
29. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005;11:71-76.
30. Carafa V, Miceli M, Altucci L, Nebbioso A: Histone deacetylase inhibitors: A patent review (2009 - 2011). Expert Opin Ther Pat 2013;23:1-17.
31. Chopin V, Slomianny C, Hondermarck H, Le Bourhis X: Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and tnf-alpha, trail, or anti-fas agonist antibody involves enhancement of death receptors' signaling and requires p21(waf1). Exp Cell Res 2004;298:560-573.
32. Xu SQ, El-Deiry WS: P21(waf1/cip1) inhibits initiator caspase cleavage by trail death receptor dr4. Biochem Biophys Res Commun 2000;269:179-190.
33. Vignot S, Faivre S, Aguirre D, Raymond E: Mtor-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-537.